Cardura, tablets 1 mg 30 pcs

How to take, the dosage

The drug may be prescribed to be taken both in the morning and in the evening.

In benign prostatic hyperplasia: The starting dose of Cardura is 1 mg once daily to minimize the possibility of postural hypotension and/or syncope (syncope). Depending on individual urodynamics and the presence of symptoms of BPH, the dose may be increased to 2 mg and then to 4 mg up to a maximum recommended dose of 8 mg. The recommended interval for increasing the dose is 1-2 weeks. The average recommended dose is 2-4 mg once daily.

In arterial hypertension: The dose of the drug varies from 1 to 16 mg/day. It is recommended to start treatment with 1 mg once daily for 1 or 2 weeks in order to minimize the possibility of developing postural hypotension and/or syncope (fainting). Over the next 1 or 2 weeks, the dose may be increased to 2 mg once daily. To achieve the desired BP reduction, if necessary, the daily dose should be increased gradually, observing even intervals, up to 4 mg, 8 mg and up to a maximum of 16 mg, depending on the severity of the patient’s reaction. The average dose is 2-4 mg once daily.

Application in renal impairment: The pharmacokinetics of doxazosin in patients with renal impairment are not altered, and the drug itself does not aggravate the existing renal impairment, so in patients in this group Cardura is used in normal doses.

Use in elderly patients: No dosing adjustment is required when prescribing the drug in elderly patients.

– Administration in children There is no experience with the use of Cardura in children.

For ease of dosing, you can use Cardura 2 mg tablet pack. 30 Pfizer or Cardura tbl. 4 mg ref. 30 Pfizer .

Interaction

The co-administration of Cardura with FDE type 5 inhibitors in some patients may lead to symptomatic hypotension.

The majority (98%) of doxazosin in blood plasma is bound to proteins. The results of human plasma in vitro studies indicate that doxazosin does not affect the binding to proteins of digoxin, warfarin, phenytoin or indomethacin. In clinical practice, Cardura has been used without any evidence of interaction with thiazide diuretics, furosemide, beta-adrenoblockers, NSAIDs, antibiotics, oral hypoglycemic agents, uricosuric agents and anticoagulants.

On a single use of Cardura at a dose of 1 mg/day for 4 days and concomitant administration of cimetidine at a dose of 400 mg 2 times/day a 10% increase in mean AUC values and a statistically insignificant increase in mean plasma C max and mean T 1/2 of doxazosin were observed. A similar 10% increase in mean AUC values of doxazosin on cimetidine administration is within the range of variability (27%) of mean AUC values for doxazosin compared to placebo.

Special Instructions

As with any alpha-adrenoblocker treatment (especially at the start of therapy), a very small percentage of patients have experienced postural hypotension manifested by dizziness and weakness or loss of consciousness (fainting). Before starting any alpha-adrenoblocker prescription, patients should be advised how to avoid the symptoms of postural hypotension. At the beginning of treatment with Cardura, the patient should be advised to exercise caution in case of weakness or dizziness.

Caution should be exercised when using Cardura with phosphodiesterase type 5 inhibitors because this may cause symptomatic hypotension in some patients.

Application in hepatic impairment: Caution should be exercised when prescribing Cardura, as well as other fully biotransformable drugs in patients with hepatic impairment, avoiding prescribing maximum doses.

Application in renal impairment: The pharmacokinetics of doxazosin do not change in patients with renal impairment and the drug itself does not aggravate the existing renal impairment, therefore in patients in this group Cardura is used in normal doses.

Impact on driving and operating machinery: When prescribing Cardura it should be taken into account that the ability to drive vehicles and operate machinery may worsen, especially at the beginning of treatment. Dizziness may occur.

Contraindications

• high sensitivity to quinazolines, doxazosin or any of the excipients of the drug

.

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
• age
• under 18 years of age;
• urinary tract infections;
• anuria;
• progressive renal failure;
• hypotension and tendency to orthostatic disturbances (includingч.
• Hypotension and predisposition to orthostatic complaints (including history);
• Compatible upper urinary tract obstruction.

With caution: Mitral and aortic stenosis, heart failure with increased minute output, right ventricular failure due to pulmonary embolism or exudative pericarditis, left ventricular failure with low filling pressure, cerebral circulatory disorders, advanced age, concurrent use with phosphodiesterase type 5 (PDE-5) inhibitors, as.as symptomatic hypotension, hepatic insufficiency may occur.

Side effects

DGID

According to controlled clinical studies, the same adverse reactions have been reported in patients with DPH as in patients with arterial hypertension.

The following adverse reactions have been reported in post-marketing use of the drug.

Hematopoietic and lymphatic system disorders: very rare – leukopenia, thrombocytopenia.

Hearing and vestibular system disorders: infrequent – tinnitus.

Visual organ: often – color perception disorders; infrequent – atonic iris syndrome.

Gastrointestinal disorders: frequently – abdominal pain, diarrhea, dyspepsia, dry oral mucosa; infrequently – flatulence, constipation, vomiting.

Liver: very rarely cholestasis, hepatitis, jaundice.

The immune system: very rare – anaphylactic reactions.

Laboratory measures: infrequent – weight gain; very rare – increase in liver transaminase activity.

Metabolic disorders: infrequent – anorexia.

Musculoskeletal system: infrequent – arthralgia, back pain, muscle cramps, muscle weakness, myalgia.

CNS and peripheral nervous system: often – paresthesia; infrequently – hypoesthesia, tremor.

Psychiatric disorders: often – agitation, anxiety, insomnia; rarely – depression.

Transureting system disorders: infrequent increased frequency of urination, polyuria, urinary incontinence; very rare – dysuria, hematuria, nicturia.

Reproductive system disorders: very rarely – gynecomastia, impotence, priapism; very rarely – retrograde ejaculation.

Respiratory system: often – shortness of breath, rhinitis; infrequent – cough, nasal bleeding; very rare – exacerbation of existing bronchospasm.

The skin: infrequent – alopecia, skin itching, skin rash, purpura; very rare – urticaria.

Systemic system disorders: infrequent – skin rush, significant decrease in blood pressure, postural hypotension.

Others: infrequent – pain of different localization.

Arterial hypertension

In controlled clinical trials of Cardura, the most common adverse reactions were postural (occasionally associated with syncope) or nonspecific, which included the reactions listed below.

Hearing and vestibular system disorders: frequently, vertigo.

Gastrointestinal disorders: often – nausea.

CNS and peripheral nervous system disorders: very often – dizziness, headache; often – postural dizziness (after the first dose a marked decrease in BP may occur, which may lead to orthostatic vertigo, in severe cases, especially with rapid transition from lying to standing or sitting position – to fainting), drowsiness.

Respiratory system: often – rhinitis.

Others: often – asthenia, swelling of the lower extremities, fatigue, weakness.

Overdose

Symptoms: marked BP decrease, sometimes accompanied by fainting.

Treatment: the patient should be immediately placed on his back and legs elevated; if necessary, symptomatic therapy should be carried out. Binding of doxazosin to plasma proteins is high, so dialysis is ineffective.

Similarities

Cardura, Doxazosin, Doxazosin-Teva, Doxazosin-FPO